Cell Genesys (CEGE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (965)	6/20/2000 4:47:00 PM
From: david james	Read Replies (2) of 1298

This may be part of the reason that ABGX is moving. Sounds like a fairly broad patent. Should be an announcement on it soon. marketjury.com ABGX #6,075,181 Issued: June 13, 2000 Human antibodies derived from immunized xenomice ABSTRACT Antibodies with fully human variable regions against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof. ---------------------------- CEGE book value increased by $69 million (2$/share) with the move in ABGX today (they have 4.852 million shares of ABGX). Not sure why CEGE has yet to respond .... The link does not work well, but it is here too 164.195.100.11 Or try 164.195.100.11 and put in number 6075181

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next